Changes in Hong Kong stocks | Rongchang Biotech (09995) fell more than 7%, and the loss in the first quarter increased to 349 million yuan year-on-year, and previously announced a planned increase of 2.55 billion yuan

Rongchang Biotech (09995) fell by more than 7%. As of press release, it was down 7.54% to HK$28.2, with a turnover of HK$483.39 million.

Zhitong FinanceApr 28 23:19 ET

Great Week for RemeGen Co., Ltd. (HKG:9995) Institutional Investors After Losing 33% Over the Previous Year

Key Insights Given the large stake in the stock by institutions, RemeGen's stock price might be vulnerable to their trading decisions The top 8 shareholders own 51% of the company 12% of RemeGen

Simply Wall StApr 27 22:46 ET

榮昌生物：2024年第一季度報告

Futu NewsApr 26 08:31 ET · Announcements

Rongchang Biotech (688331.SH) announced first-quarter results with a net loss of 349 million yuan

Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating income during the reporting period...

Zhitong FinanceApr 26 08:05 ET

榮昌生物：2023 年度報告

Futu NewsApr 26 04:57 ET · Announcements

Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism

Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.

Zhitong FinanceApr 24 23:17 ET